Fujifilm have announced plans to make a capital investment of approximately $40 million (4 billion yen) in Fujifilm Diosynth Biotechnologies, a CDMO for biologics, viral vaccines and viral vectors, to establish a new process development and manufacturing facility for viral vectors and advanced therapies in the greater-Boston area. This will be the third location for viral vector CDMO services provided by Fujifilm Diosynth Biotechnologies.
The new facility is scheduled to begin process development operations in fall 2021 and will expand Fujifilm Diosynth Biotechnologies’ manufacturing capacity to support the viral vector sector, which is focused on using genes to treat or prevent disease. The new facility will house experimental and analytical equipment for viral vector and advanced therapy process development, with contract manufacturing services for early phase clinical trials beginning at the site in fall 2023.
In 2014, Fujifilm Corporation established viral vector manufacturing offering at the Fujifilm Diosynth Biotechnologies’ site in Texas. As the market for viral vectors has continued to expand, Fujifilm has invested approximately $120 million in the Texas site to build a new process development facility and to expand existing manufacturing facilities. Fujifilm Diosynth Biotechnologies have also recently announced an investment to provide process & analytical development and cGMP manufacturing of viral vectors in the UK.
Read the Fujifilm statement